Olaplex Holdings Files 8-K for Material Agreement

Ticker: OLPX · Form: 8-K · Filed: Aug 26, 2025 · CIK: 1868726

Sentiment: neutral

Topics: material-agreement, 8-k

Related Tickers: OLPX

TL;DR

OLPX filed an 8-K on 8/26 for a material agreement dated 8/20.

AI Summary

Olaplex Holdings, Inc. filed an 8-K on August 26, 2025, reporting a material definitive agreement entered into on August 20, 2025. The filing also includes Regulation FD disclosures and financial statements/exhibits. The company's principal executive offices are located at 432 Park Avenue South, New York, NY.

Why It Matters

This 8-K filing indicates a significant new agreement for Olaplex Holdings, Inc., which could impact its business operations and financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood by the market.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement?

The filing does not specify the details of the material definitive agreement, only that one was entered into on August 20, 2025.

When was this 8-K filing submitted?

The 8-K filing was submitted on August 26, 2025.

What is Olaplex Holdings, Inc.'s state of incorporation?

Olaplex Holdings, Inc. is incorporated in Delaware.

Where are Olaplex Holdings, Inc.'s principal executive offices located?

The principal executive offices are located at 432 Park Avenue South, Third Floor, New York, NY 10016.

What is the SIC code for Olaplex Holdings, Inc.?

The Standard Industrial Classification code for Olaplex Holdings, Inc. is 2844 (Perfumes, Cosmetics & Other Toilet Preparations).

Filing Stats: 1,027 words · 4 min read · ~3 pages · Grade level 12.8 · Accepted 2025-08-26 06:55:13

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Description 2.1*# Stock Purchase Agreement, dated August 20, 2025, among Olaplex, Inc., Purvala Bioscience, Inc., the stockholders and optionholders of Purvala Bioscience, Inc, and Shareholder Representative Services LLC, as the representative of the stockholders and optionholders. 99.1 Press Release dated August 26, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Certain annexes, exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted annexes, exhibits and schedules upon request by the SEC. # Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. The Company hereby undertakes to furnish an unredacted copy of the exhibit upon request by the SEC. Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized. Date: August 26, 2025 Olaplex Holdings, Inc. By: /s/ Amanda Baldwin Name: Amanda Baldwin Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing